Compare DFLI & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | QTTB |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 44.3M |
| IPO Year | N/A | 2018 |
| Metric | DFLI | QTTB |
|---|---|---|
| Price | $3.02 | $6.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.50 | $13.00 |
| AVG Volume (30 Days) | ★ 273.2K | 177.3K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | $17.85 | N/A |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | ★ N/A | $2.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $1.38 |
| 52 Week High | $5.15 | $7.65 |
| Indicator | DFLI | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 76.03 |
| Support Level | $2.92 | $3.75 |
| Resistance Level | $4.57 | N/A |
| Average True Range (ATR) | 0.24 | 0.60 |
| MACD | 0.06 | 0.24 |
| Stochastic Oscillator | 69.90 | 73.55 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.